485 related articles for article (PubMed ID: 18299304)
1. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.
Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM
Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304
[TBL] [Abstract][Full Text] [Related]
2. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
Debes A; Bauer M; Kremer S
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
[TBL] [Abstract][Full Text] [Related]
4. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.
Aghamohammadi A; Farhoudi A; Nikzad M; Moin M; Pourpak Z; Rezaei N; Gharagozlou M; Movahedi M; Atarod L; Afshar AA; Bazargan N; Hosseinpoor AR
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):60-4. PubMed ID: 14756466
[TBL] [Abstract][Full Text] [Related]
5. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study.
Ang GC; Werth VP
Arch Dermatol; 2005 Jul; 141(7):855-9. PubMed ID: 16027300
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis.
Kameda H; Nagasawa H; Ogawa H; Sekiguchi N; Takei H; Tokuhira M; Amano K; Takeuchi T
J Rheumatol; 2005 Sep; 32(9):1719-26. PubMed ID: 16142867
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety.
Al-Mayouf SM; Laxer RM; Schneider R; Silverman ED; Feldman BM
J Rheumatol; 2000 Oct; 27(10):2498-503. PubMed ID: 11036850
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center.
Femia AN; Eastham AB; Lam C; Merola JF; Qureshi AA; Vleugels RA
J Am Acad Dermatol; 2013 Oct; 69(4):654-7. PubMed ID: 24034377
[No Abstract] [Full Text] [Related]
10. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience.
Vo AA; Cam V; Toyoda M; Puliyanda DP; Lukovsky M; Bunnapradist S; Peng A; Yang K; Jordan SC
Clin J Am Soc Nephrol; 2006 Jul; 1(4):844-52. PubMed ID: 17699296
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
[TBL] [Abstract][Full Text] [Related]
12. Adverse reactions of intravenous immunoglobulin.
Al-Wahadneh AM; Khriesat IA; Kuda EH
Saudi Med J; 2000 Oct; 21(10):953-6. PubMed ID: 11369961
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of cutaneous lesions in juvenile dermatomyositis with high-dose intravenous immunoglobulin.
Amano H; Nagai Y; Katada K; Hashimoto C; Ishikawa O
Br J Dermatol; 2007 Jun; 156(6):1390-2. PubMed ID: 17459039
[No Abstract] [Full Text] [Related]
14. Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy.
Williams L; Chang PY; Park E; Gorson KC; Bayer-Zwirello L
Obstet Gynecol; 2007 Feb; 109(2 Pt2):561-3. PubMed ID: 17267895
[TBL] [Abstract][Full Text] [Related]
15. A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin.
Matamoros N; De Gracia J; Hernández F; Pons J; Alvarez A; Jiménez V
Int Immunopharmacol; 2005 Mar; 5(3):619-26. PubMed ID: 15683857
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura.
Bussel JB; Hanna K;
Am J Hematol; 2007 Mar; 82(3):192-8. PubMed ID: 17109385
[TBL] [Abstract][Full Text] [Related]
17. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety.
Riley P; Maillard SM; Wedderburn LR; Woo P; Murray KJ; Pilkington CA
Rheumatology (Oxford); 2004 Apr; 43(4):491-6. PubMed ID: 14722349
[TBL] [Abstract][Full Text] [Related]
18. Use of complementary and alternative medicine by pediatric patients with functional and organic gastrointestinal diseases: results from a multicenter survey.
Vlieger AM; Blink M; Tromp E; Benninga MA
Pediatrics; 2008 Aug; 122(2):e446-51. PubMed ID: 18662934
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study.
Apaz MT; Saad-Magalhães C; Pistorio A; Ravelli A; de Oliveira Sato J; Marcantoni MB; Meiorin S; Filocamo G; Pilkington C; Maillard S; Al-Mayouf S; Prahalad S; Fasth A; Joos R; Schikler K; Mozolova D; Landgraf JM; Martini A; Ruperto N;
Arthritis Rheum; 2009 Apr; 61(4):509-17. PubMed ID: 19333974
[TBL] [Abstract][Full Text] [Related]
20. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.
Nadeau JO; Bhibhatbhan A; McDougall D; Toth C
Clin Neurol Neurosurg; 2010 Jul; 112(6):467-9. PubMed ID: 20227821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
